In Vitro: Anshinone IIA+TRAIL synergistically induces apoptosis in TRAIL-resistant NSCLC cells by upregulating DR5, activating the PERK/ATF4 pathway, and suppressing the STAT3/survivin axis. The gene discussed is BIRC5; the disease is non-small cell lung carcinoma.